| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
GPR88-IN-1 specifically targets GPR88, an orphan G protein-coupled receptor that is highly expressed in the striatum and plays a role in modulating dopaminergic signaling. It acts as an antagonist, blocking the receptor's activity. This makes it a key tool for investigating the role of GPR88 in various central nervous system disorders, including schizophrenia and drug addiction.
|
|---|---|
| ln Vitro |
In vitro, GPR88-IN-1 is a selective inhibitor of GPR88. Its activity is characterized by its ability to block GPR88-mediated signaling pathways. It is used in cell-based assays to study the receptor's function and to validate it as a potential therapeutic target for CNS disorders.
|
| ln Vivo |
In vivo activity data for GPR88-IN-1 are not extensively detailed in the search results. As a selective GPR88 inhibitor, it is a valuable tool for studying the role of this receptor in various CNS disorders. It can be used in animal models to investigate the effects of GPR88 blockade on behavior and neurochemistry.
|
| Enzyme Assay |
For non-cellular in vitro receptor binding assays, GPR88-IN-1 is characterized using radioligand binding or other biophysical techniques to confirm its affinity and selectivity for GPR88. These assays are essential for establishing its mechanism of action as a direct antagonist at the receptor.
|
| Cell Assay |
For in vitro cellular assays, the activity of GPR88-IN-1 is evaluated in cells expressing GPR88. A typical functional assay measures its ability to inhibit agonist-induced signaling, such as the inhibition of cAMP accumulation. Its antagonistic activity is confirmed by its ability to block the receptor's response to its agonist.
|
| Animal Protocol |
In vivo animal studies with GPR88-IN-1 would typically be conducted in mouse or rat models to investigate the role of GPR88 in CNS disorders. For example, it could be used in models of schizophrenia, drug addiction, or Parkinson's disease. The compound can be administered via various routes, including intraperitoneal injection or oral gavage, depending on the study design.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for GPR88-IN-1 are not extensively documented. As a small-molecule antagonist with a molecular weight of 416.52, it is expected to have moderate oral bioavailability and the ability to cross the blood-brain barrier to reach its target in the CNS. Its solubility and formulation for in vivo studies would need to be determined empirically.
|
| Toxicity/Toxicokinetics |
Toxicological data for GPR88-IN-1 are limited. As a research compound, it is intended for laboratory use only and not for human therapeutic applications. Its safety profile has not been established for clinical use. At the concentrations used in research, it is generally considered to have low toxicity, but standard laboratory safety practices should always be followed.
|
| References | |
| Additional Infomation |
GPR88-IN-1 is a selective inhibitor (antagonist) of GPR88. It has a molecular weight of 416.52 and a molecular formula of C25H28N4O2. GPR88 is a receptor involved in modulating dopaminergic signaling and is implicated in CNS disorders such as schizophrenia and drug addiction. This compound is a key research tool for studying GPR88 function.
|
| Exact Mass |
416.221
|
|---|---|
| CAS # |
714265-50-6
|
| PubChem CID |
9909836
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
548
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC(CC1)CNC2=NC=C(C(=N2)NC3=CC=CC=C3CC4=CC=CC=C4)C(=O)O
|
| InChi Key |
XZFTUBCGJFWCHL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H28N4O2/c30-24(31)21-17-27-25(26-16-19-11-5-2-6-12-19)29-23(21)28-22-14-8-7-13-20(22)15-18-9-3-1-4-10-18/h1,3-4,7-10,13-14,17,19H,2,5-6,11-12,15-16H2,(H,30,31)(H2,26,27,28,29)
|
| Chemical Name |
4-(2-benzylanilino)-2-(cyclohexylmethylamino)pyrimidine-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
